Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite strategic initiatives and partnerships, Cryoport faces challenges with a 5% revenue decline and reduced gross margins. Improved guidance and strategic partnerships may not offset current financial weaknesses, leading to a likely negative stock reaction.
Key Financial Performance
Revenue $68.2 million, a decrease of 5% year-over-year, primarily due to reduced demand in the biopharma sector.
Gross Margin 58.3%, a decline of 2.1 percentage points year-over-year, attributed to increased operational costs.
Operating Expenses $35.4 million, an increase of 3% year-over-year, driven by higher R&D investments.
Net Income $4.5 million, a decrease of 12% year-over-year, due to lower revenue and higher expenses.
Cash Flow from Operations $12.8 million, an increase of 8% year-over-year, supported by improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are based on management's beliefs and assumptions, which may not materialize as expected. This introduces risks related to reliance on projections and assumptions that may not hold true.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Cryoport is focusing on expanding its global supply chain network to support the growing demand for cell and gene therapies. The company is investing in new technologies to enhance its temperature-controlled supply chain solutions. Additionally, Cryoport is exploring strategic partnerships to strengthen its market position and drive future growth.
Revenue Expectations: Cryoport expects its revenue to grow by 15% to 20% in the next fiscal year, driven by increased demand for its advanced supply chain solutions in the life sciences sector.
Margin Projections: The company anticipates an improvement in gross margins by 2% to 3% due to operational efficiencies and cost management strategies.
Capital Expenditures: Cryoport plans to increase its capital expenditures by approximately 10% to expand its infrastructure and support future growth initiatives.
Market Trends: The company expects a continued strong demand for cell and gene therapies, which will drive the need for reliable and scalable supply chain solutions.
Business Segment Performance: Cryoport projects significant growth in its life sciences segment, particularly in the areas of cell and gene therapy logistics.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anna Snopkowski
CEO Sawicki
Capital Markets
Chairman President
Communications statement
Cryoport Full
Division Anna
Division Etoch
Division Larsen
Division PM
Division Saxon
Division Subhalaxmi
EST Kanan
Etoch Stephens
Full Conference
Heinzen Vice
Inc Research
Inc afternoon
Jerrell Shelton
KeyBanc Capital
LLC Research
Markets Inc
Officer Heinzen
PM EST
Relations Puneet
Research Division
Sawicki Senior
Saxon Needham
Senior VP
Snopkowski KeyBanc
Subhalaxmi Nambi
host KCSA
CYRX Transcript
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
Unknown3-3
Despite strategic initiatives and partnerships, Cryoport faces challenges with a 5% revenue decline and reduced gross margins. Improved guidance and strategic partnerships may not offset current financial weaknesses, leading to a likely negative stock reaction.
Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights reaffirmed revenue guidance for 2025 and a strong outlook for commercial revenue growth, supported by FDA approvals. The strategic partnership with DHL is expected to enhance capabilities, and there is optimism for regulatory approvals. While there are some uncertainties, such as the gene therapy pause and lack of profitability guidance for 2026, the overall sentiment is positive, particularly with the potential for market expansion and strategic initiatives. The Q&A session further supports this with positive analyst sentiment and no significant concerns about market exits.
Cryoport, Inc. (CYRX) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reflect a generally positive outlook. The strategic partnership with DHL, strong demand in clinical trials, and positive customer feedback indicate growth potential. Gross margins are stable, and the company's strategic focus on Life Sciences and new product launches are promising. Although there are uncertainties like the impact of FDA's REMS update and competitive dynamics, the overall sentiment is optimistic, supported by robust financial metrics and strategic initiatives. The positive response to being more carrier-agnostic post-DHL transaction further strengthens the outlook.
Cryoport, Inc. (NASDAQ:CYRX) Q1 2025 Earnings Call Transcript
Positive5-8
The earnings call reveals strong financial performance with 10% revenue growth and a strategic partnership with DHL, enhancing market positioning. Guidance for 2025 shows continued growth, and management is optimistic about market conditions and shareholder value. The Q&A confirms positive market sentiment, with strong growth in services and a strategic focus on leveraging partnerships and new product launches. Despite some unclear responses, the overall sentiment is positive, supported by robust growth in key areas and strategic initiatives.
CYRX Slides
CYRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
